Payment overview · 2025
General Payments
$1,478.30
36 reported records · 15 companies
Healthcare provider profile · identity verified
Rafael O Robledo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAMMOND, LA · NPI 1497965198
Verified facts
What the public records show
CMS Open Payments records show Rafael O Robledo, M.D. received $1,478.30 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rexulti, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 703 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $319.52 | 21.6% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $261.23 | 17.7% | 9 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $239.28 | 16.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.56 | 10.1% | 3 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $146.48 | 9.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $118.24 | 8.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.22 | 4.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.13 | 2.6% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $31.86 | 2.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.65 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.30 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.00 | 1.3% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.08 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.84 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.91 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,478.30 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $261.23 | 9 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $239.28 | 3 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $146.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.40 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $127.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $118.24 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $80.06 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $67.61 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.13 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.01 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 703 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 205 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
205 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
703 | 91 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1140 | 207 |
| Pantoprazole Sodium | Pantoprazole Sodium | 886 | 164 |
| Gabapentin | Gabapentin | 811 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 751 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 748 | 130 |
| Furosemide | Furosemide | 741 | 149 |
| Eliquis | Apixaban | 703 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 550 | 108 |
| Clopidogrel | Clopidogrel Bisulfate | 535 | 100 |
| Potassium Chloride | Potassium Chloride | 521 | 87 |
| Trazodone Hcl | Trazodone Hcl | 455 | 84 |
| Lisinopril | Lisinopril | 446 | 78 |
| Mirtazapine | Mirtazapine | 397 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 391 | 55 |
| Carvedilol | Carvedilol | 355 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 347 | 65 |
| Losartan Potassium | Losartan Potassium | 345 | 58 |
| Metformin Hcl | Metformin Hcl | 319 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 307 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 300 | 58 |
| Sertraline Hcl | Sertraline Hcl | 271 | 47 |
| Spironolactone | Spironolactone | 264 | 42 |
| Nifedipine Er | Nifedipine | 260 | 49 |
| Omeprazole | Omeprazole | 252 | 47 |
| Famotidine | Famotidine | 245 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 243 | 46 |
| Memantine Hcl | Memantine Hcl | 241 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 237 | 75 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 237 | 51 |
| Alprazolam | Alprazolam | 219 | 42 |
| Levetiracetam | Levetiracetam | 215 | 37 |
| Donepezil Hcl | Donepezil Hcl | 214 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 210 | 34 |
| Farxiga | Dapagliflozin Propanediol | 205 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 197 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 193 | 42 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 192 | 43 |
| Entresto | Sacubitril/Valsartan | 173 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 33 |
| Allopurinol | Allopurinol | 170 | 29 |
| Jardiance | Empagliflozin | 167 | 31 |
| Myrbetriq | Mirabegron | 167 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 167 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 164 | 28 |
| Methocarbamol | Methocarbamol | 159 | 39 |
| Montelukast Sodium | Montelukast Sodium | 158 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 149 | 43 |
| Simvastatin | Simvastatin | 149 | 22 |
| Baclofen | Baclofen | 138 | 22 |
| Ozempic | Semaglutide | 134 | 26 |
| Finasteride | Finasteride | 132 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 132 | 25 |
| Divalproex Sodium | Divalproex Sodium | 128 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 125 | 32 |
| Prednisone | Prednisone | 123 | 64 |
| Buspirone Hcl | Buspirone Hcl | 122 | 21 |
| Meloxicam | Meloxicam | 119 | 28 |
| Ondansetron Odt | Ondansetron | 119 | 50 |
| Olanzapine | Olanzapine | 114 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 112 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 108 | 12 |
| Tramadol Hcl | Tramadol Hcl | 104 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 41 |
| Xarelto | Rivaroxaban | 101 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 95 | 31 |
| Ranolazine Er | Ranolazine | 95 | 11 |
| Novolog Flexpen | Insulin Aspart | 94 | 19 |
| Latanoprost | Latanoprost | 93 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 87 | 12 |
| Januvia | Sitagliptin Phosphate | 86 | 13 |
| Sucralfate | Sucralfate | 86 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 85 | 16 |
| Pregabalin | Pregabalin | 82 | 18 |
| Bupropion Xl | Bupropion Hcl | 81 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 16 |
| Ibuprofen | Ibuprofen | 80 | 29 |
| Clonidine Hcl | Clonidine Hcl | 79 | 27 |
| Linzess | Linaclotide | 73 | 19 |
| Calcitriol | Calcitriol | 72 | suppressed |
| Lorazepam | Lorazepam | 72 | 18 |
| Oxcarbazepine | Oxcarbazepine | 71 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 71 | 13 |
| Risperidone | Risperidone | 71 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 69 | 15 |
| Trulicity | Dulaglutide | 69 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 68 | suppressed |
| Diazepam | Diazepam | 67 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 67 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 18 |
| Aripiprazole | Aripiprazole | 66 | 17 |
| Cefdinir | Cefdinir | 66 | 56 |
| Cephalexin | Cephalexin | 66 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 66 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 38 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 63 | 19 |
| Ezetimibe | Ezetimibe | 62 | 13 |
| Nystatin | Nystatin | 62 | 39 |
| Topiramate | Topiramate | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Mounjaro | Tirzepatide | 56 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 55 | 20 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Estradiol | Estradiol | 51 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 20 |
| Azithromycin | Azithromycin | 50 | 45 |
| Lidocaine | Lidocaine | 50 | 14 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Lactulose | Lactulose | 49 | 28 |
| Temazepam | Temazepam | 49 | 17 |
| Gemtesa | Vibegron | 48 | suppressed |
| Mupirocin | Mupirocin | 46 | 27 |
| Atenolol | Atenolol | 45 | 13 |
| Ramipril | Ramipril | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 13 |
| Fluconazole | Fluconazole | 43 | 29 |
| Levemir Flexpen | Insulin Detemir | 43 | suppressed |
| Nateglinide | Nateglinide | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Meclizine Hcl | Meclizine Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Sodium Chloride | 0.9 % Sodium Chloride | 39 | 14 |
| Primidone | Primidone | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 13 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 14 |
| Levofloxacin | Levofloxacin | 36 | 26 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 36 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 21 |
| Brilinta | Ticagrelor | 35 | suppressed |
| Daptomycin | Daptomycin | 35 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 11 |
| Cefepime Hcl | Cefepime Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 34 | suppressed |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 33 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 33 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Colchicine | Colchicine | 32 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Meropenem | Meropenem | 31 | suppressed |
| Nabumetone | Nabumetone | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | 11 |
| Novolin R Flexpen | Insulin Regular, Human | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 26 |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Clonidine | Clonidine | 29 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 28 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Cyclosporine | Cyclosporine | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Xifaxan | Rifaximin | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Gvoke | Glucagon | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 20 |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 11 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Captopril | Captopril | 15 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Nystop | Nystatin | 13 | 11 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fluorometholone | Fluorometholone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Proctofoam-Hc | Hydrocortisone/Pramoxine | 11 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,478.30 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FUROSCIX, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, SPRAVATO, UROLIFT, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error